MARKET

DRRX

DRRX

DURECT
NASDAQ
1.010
+0.147
+17.09%
After Hours: 0.9210 -0.089 -8.81% 17:17 11/22 EST
OPEN
0.8880
PREV CLOSE
0.8626
HIGH
1.040
LOW
0.8880
VOLUME
165.37K
TURNOVER
--
52 WEEK HIGH
1.880
52 WEEK LOW
0.4810
MARKET CAP
31.35M
P/E (TTM)
-1.8179
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DRRX last week (1111-1115)?
Weekly Report · 5d ago
Based on the provided financial report, the title of the article is: "Form 10-Q: Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" This title indicates that the report is a quarterly report filed by Durect Corporation with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.
Press release · 11/14 22:59
Northland Securities Sticks to Its Buy Rating for Durect (DRRX)
TipRanks · 11/14 13:56
Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
TipRanks · 11/14 13:06
H.C. Wainwright Remains a Hold on Durect (DRRX)
TipRanks · 11/14 11:27
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 11/14 11:20
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/13 22:10
Durect reports Q3 EPS (14c), consensus (17c)
TipRanks · 11/13 21:05
More
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.